Who is sponsoring NCT00505882?

NCT00505882 is sponsored by University of Texas Southwestern Medical Center.

What condition does NCT00505882 study?

NCT00505882 studies Type 1 Diabetes.

What drugs are being tested in NCT00505882?

Interventions: Pramlintide, Glargine, Lispro, Aspart.

What is the status of NCT00505882?

NCT00505882 is currently WITHDRAWN.

Last reviewed 2019-01-04 · How we verify

The Pilot Study:Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes

NCT00505882 Phase 4 WITHDRAWN

In this pilot study we are evaluating the efficacy of pramlintide on preventing weight gain among early onset type 1 diabetes. We are also evaluating the safety and the effects of treatment with pramlintide on early diagnosed type 1 diabetic subjects, especially among pediatric subjects.

Details

Lead sponsor	University of Texas Southwestern Medical Center
Phase	Phase 4
Status	WITHDRAWN
Start date	2007-07
Completion	2008-12

Conditions

Type 1 Diabetes

Interventions

Pramlintide
Glargine
Lispro
Aspart

Primary outcomes

The change in weight (kg) will be compared between as well as within the placebo and the pramlintide treatment group from baseline to the end of the study. — 6 months

Countries

United States